ICON Public Limited Company Stock

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-31 pm EDT 5-day change 1st Jan Change
324.8 USD +0.59% Intraday chart for ICON Public Limited Company +1.28% +14.75%
Sales 2024 * 8.64B Sales 2025 * 9.3B Capitalization 26.86B
Net income 2024 * 827M Net income 2025 * 1B EV / Sales 2024 * 3.37 x
Net Debt 2024 * 2.27B Net Debt 2025 * 1.17B EV / Sales 2025 * 3.01 x
P/E ratio 2024 *
32.4 x
P/E ratio 2025 *
26.5 x
Employees 41,150
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.35%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on ICON Public Limited Company

1 day+0.59%
1 week+1.28%
1 month+9.04%
3 months+1.31%
6 months+21.68%
Current year+14.75%
More quotes
1 week
306.62
Extreme 306.62
332.52
1 month
295.75
Extreme 295.75
332.52
Current year
244.59
Extreme 244.59
344.77
1 year
215.88
Extreme 215.88
344.77
3 years
171.43
Extreme 171.43
344.77
5 years
104.28
Extreme 104.275
344.77
10 years
41.53
Extreme 41.53
344.77
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 11-10-31
Director of Finance/CFO 45 05-12-31
Chairman 61 05-10-02
Members of the board TitleAgeSince
Founder 71 90-05-31
Chief Executive Officer 63 11-10-31
Director/Board Member 68 21-06-30
More insiders
Date Price Change Volume
24-05-31 324.8 +0.59% 674,254
24-05-30 322.9 +4.33% 1,021,066
24-05-29 309.5 -3.59% 493,152
24-05-28 321.1 +0.11% 566,423
24-05-24 320.7 +0.23% 582,318

Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT

More quotes
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
324.8 USD
Average target price
363.1 USD
Spread / Average Target
+11.80%
Consensus